TuisLSTA • NASDAQ
add
Lisata Therapeutics Inc
Vorige sluiting
$2,63
Dagwisseling
$2,53 - $2,67
Jaarwisseling
$1,87 - $4,20
Markkapitalisasie
22,18 m USD
Gemiddelde volume
13,05 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 5,85 m | -11,42% |
Netto inkomste | -4,72 m | 12,53% |
Netto winsgrens | — | — |
Wins per aandeel | -0,55 | 15,38% |
EBITDA | -5,80 m | 11,46% |
Effektiewe belastingkoers | 16,92% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 25,83 m | -40,41% |
Totale bates | 28,98 m | -39,92% |
Totale aanspreeklikheid | 3,88 m | -29,43% |
Totale ekwiteit | 25,10 m | — |
Uitstaande aandele | 8,60 m | — |
Prys om te bespreek | 0,90 | — |
Opbrengs op bates | -45,69% | — |
Opbrengs op kapitaal | -53,50% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -4,72 m | 12,53% |
Kontant van bedrywe | -5,40 m | 23,13% |
Kontant van beleggings | 9,43 m | 46,54% |
Kontant van finansiering | -23,00 k | 83,80% |
Netto kontantverandering | 4,01 m | 608,63% |
Beskikbare kontantvloei | -4,32 m | 24,29% |
Meer oor
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Gestig
1980
Webwerf
Werknemers
26
